CIK 0000072444 · Accelerated filer<br>Smaller reporting company
Vaxart, Inc.
Sign in to watch- Ticker
- VXRT
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 591212264
- Phone
- (650) 550-3500
- Business address
- 310 UTAH AVENUE, SUITE 150, SOUTH SAN FRANCISCO, CA
- Former names
- Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., NABI BIOPHARMACEUTICALS, NABI BIOPHARMACEUTICALS, NABI /DE/, NORTH AMERICAN BIOLOGICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-08-04 | Wheadon David E. Director | Grant or award | +7,375 | 7,375 | ||
| 2022-08-04 | Wheadon David E. Director | Grant or award · Stock Option (right to buy) | +44,224 | 44,224 | ||
| 2022-08-04 | Finney Michael J. Director | Grant or award | +7,375 | 663,465 | ||
| 2022-08-04 | Finney Michael J. Director | Grant or award · Stock Option (right to buy) | +44,224 | 44,224 | ||
| 2022-08-04 | Davis Todd C Director | Grant or award | +7,375 | 125,905 | ||
| 2022-08-04 | Davis Todd C Director | Grant or award · Stock Option (right to buy) | +44,224 | 44,224 | ||
| 2022-08-04 | Cherrington Julie M Director | Grant or award | +6,217 | 6,217 | ||
| 2022-08-04 | Cherrington Julie M Director | Grant or award · Stock Option (right to buy) | +37,280 | 37,280 | ||
| 2022-06-22 | Ahmad Fuad Interim CFO | Purchase | +5,000 | $3.22 | $16K | 5,000 |
| 2022-04-22 | Tucker Sean SVP, Chief Scientific Officer | Option exercise | +40,000 | $0.77 | $31K | 127,631 |
| 2022-04-22 | Tucker Sean SVP, Chief Scientific Officer | Option exercise · Stock Option (right to buy) | −40,000 | 84,061 | ||
| 2022-03-28 | Cummings James F. Chief Medical Officer | Grant or award | +43,750 | 43,750 | ||
| 2022-03-28 | Cummings James F. Chief Medical Officer | Grant or award · Stock Option (right to buy) | +262,500 | 262,500 | ||
| 2022-03-28 | Floroiu Cezar Andrei President, Chief Exec Officer | Grant or award | +85,000 | 85,000 | ||
| 2022-03-28 | Floroiu Cezar Andrei President, Chief Exec Officer | Grant or award · Stock Option (right to buy) | +550,000 | 550,000 | ||
| 2022-03-28 | Tucker Sean SVP, Chief Scientific Officer | Grant or award | +43,750 | 87,631 | ||
| 2022-03-28 | Tucker Sean SVP, Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +262,500 | 262,500 | ||
| 2022-01-10 | Yedid Robert A. Director | Sale | −1,500 | $6.01 | $9K | 0 |
Page 10 of 10 · 198 trades